OIVD Creates Internal Adverse Events Database; CoA Requirements Rare
This article was originally published in The Gray Sheet
Executive Summary
FDA's in vitro diagnostics office recently established an in-house adverse events database to make a wider selection of post-approval information available to OIVD premarket review staff